Header Logo

Connection

JORGE E CORTES to Prognosis

Back to Details
This is a "connection" page, showing publications JORGE E CORTES has written about Prognosis.
JORGE E CORTES
Connection Strength
2.278
Prognosis
  1. Determination of fitness and therapeutic options in older patients with acute myeloid leukemia. Am J Hematol. 2021 04 01; 96(4):493-507.
    View in: PubMed
    Score: 0.053
  2. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. 2020 11; 34(11):2914-2924.
    View in: PubMed
    Score: 0.050
  3. Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2019 08; 19(8):509-515.e1.
    View in: PubMed
    Score: 0.047
  4. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019 02; 33(2):379-389.
    View in: PubMed
    Score: 0.045
  5. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018 07; 19(7):889-903.
    View in: PubMed
    Score: 0.044
  6. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018 07 26; 132(4):393-404.
    View in: PubMed
    Score: 0.043
  7. Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer. 2018 03 15; 124(6):1160-1168.
    View in: PubMed
    Score: 0.042
  8. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer. 2017 Nov 15; 123(22):4391-4402.
    View in: PubMed
    Score: 0.041
  9. Mutations in AML: prognostic and therapeutic implications. Hematology Am Soc Hematol Educ Program. 2016 Dec 02; 2016(1):348-355.
    View in: PubMed
    Score: 0.039
  10. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer. 2017 02 01; 123(3):459-467.
    View in: PubMed
    Score: 0.039
  11. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer. 2016 Nov 15; 122(21):3336-3343.
    View in: PubMed
    Score: 0.039
  12. Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015. Mayo Clin Proc. 2015 Oct; 90(10):1440-54.
    View in: PubMed
    Score: 0.036
  13. Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S276-81.
    View in: PubMed
    Score: 0.031
  14. The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):302-6.
    View in: PubMed
    Score: 0.030
  15. Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure. J Natl Compr Canc Netw. 2012 Oct 01; 10 Suppl 3:S1-S13.
    View in: PubMed
    Score: 0.030
  16. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 2012 Sep 27; 120(13):2573-80.
    View in: PubMed
    Score: 0.029
  17. Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. Cancer. 2012 Jun 15; 118(12):3116-22.
    View in: PubMed
    Score: 0.028
  18. Molecular resistance: an early indicator for treatment change? Clin Lymphoma Myeloma Leuk. 2012 Apr; 12(2):79-87.
    View in: PubMed
    Score: 0.028
  19. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012 Mar 01; 119(9):1981-7.
    View in: PubMed
    Score: 0.028
  20. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood. 2011 Oct 27; 118(17):4541-6; quiz 4759.
    View in: PubMed
    Score: 0.027
  21. FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era? Cancer. 2011 Aug 01; 117(15):3293-304.
    View in: PubMed
    Score: 0.026
  22. Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood. 2011 Feb 10; 117(6):1822-7.
    View in: PubMed
    Score: 0.026
  23. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer. 2011 Mar 01; 117(5):982-91.
    View in: PubMed
    Score: 0.026
  24. Monitoring molecular response in chronic myeloid leukemia. Cancer. 2011 Mar 15; 117(6):1113-22.
    View in: PubMed
    Score: 0.026
  25. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica. 2011 Jan; 96(1):62-8.
    View in: PubMed
    Score: 0.026
  26. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood. 2009 May 21; 113(21):5058-63.
    View in: PubMed
    Score: 0.023
  27. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood. 2009 Mar 05; 113(10):2154-60.
    View in: PubMed
    Score: 0.023
  28. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood. 2008 Dec 15; 112(13):4839-42.
    View in: PubMed
    Score: 0.022
  29. Imatinib therapy for chronic myeloid leukemia: where do we go now? J Clin Oncol. 2008 Jul 10; 26(20):3308-9.
    View in: PubMed
    Score: 0.022
  30. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer. 2007 Apr 15; 109(8):1556-60.
    View in: PubMed
    Score: 0.020
  31. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006 Oct; 20(10):1767-73.
    View in: PubMed
    Score: 0.019
  32. New strategies in chronic myeloid leukemia. Int J Hematol. 2006 May; 83(4):289-93.
    View in: PubMed
    Score: 0.019
  33. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer. 2006 Mar 15; 106(6):1306-15.
    View in: PubMed
    Score: 0.019
  34. New targeted approaches in chronic myeloid leukemia. J Clin Oncol. 2005 Sep 10; 23(26):6316-24.
    View in: PubMed
    Score: 0.018
  35. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. Cancer. 2005 Aug 15; 104(4):777-80.
    View in: PubMed
    Score: 0.018
  36. The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. Leuk Lymphoma. 2005 Jul; 46(7):993-7.
    View in: PubMed
    Score: 0.018
  37. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005 May 01; 11(9):3425-32.
    View in: PubMed
    Score: 0.018
  38. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer. 2004 Jun 01; 100(11):2396-402.
    View in: PubMed
    Score: 0.017
  39. Imatinib mesylate in the treatment of chronic myelogenous leukemia. Int J Hematol. 2004 Jun; 79(5):411-9.
    View in: PubMed
    Score: 0.017
  40. Natural history and staging of chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004 Jun; 18(3):569-84, viii.
    View in: PubMed
    Score: 0.017
  41. Clonal evolution in chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004 Jun; 18(3):671-84, x.
    View in: PubMed
    Score: 0.017
  42. Testing the prognostic model of Marin et al in an independent chronic myelogenous leukemia study group. Leukemia. 2004 Mar; 18(3):650.
    View in: PubMed
    Score: 0.016
  43. New agents in acute myeloid leukemia and other myeloid disorders. Cancer. 2004 Feb 01; 100(3):441-54.
    View in: PubMed
    Score: 0.016
  44. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003 Sep 15; 98(6):1105-13.
    View in: PubMed
    Score: 0.016
  45. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003 May 01; 97(9):2225-8.
    View in: PubMed
    Score: 0.015
  46. CMML: a biologically distinct myeloproliferative disease. Curr Hematol Rep. 2003 May; 2(3):202-8.
    View in: PubMed
    Score: 0.015
  47. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2003 Mar 01; 97(5):1234-41.
    View in: PubMed
    Score: 0.015
  48. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003 May 15; 101(10):3794-800.
    View in: PubMed
    Score: 0.015
  49. Advanced-phase chronic myeloid leukemia. Semin Hematol. 2003 Jan; 40(1):79-86.
    View in: PubMed
    Score: 0.015
  50. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res. 2002 Jul; 8(7):2177-87.
    View in: PubMed
    Score: 0.015
  51. Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome?positive leukemias. Leuk Res. 2021 12; 111:106690.
    View in: PubMed
    Score: 0.014
  52. Central nervous system involvement in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2001 Feb; 15(1):145-62.
    View in: PubMed
    Score: 0.013
  53. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. Leuk Lymphoma. 2021 01; 62(1):224-228.
    View in: PubMed
    Score: 0.013
  54. Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies. Hematol Oncol. 2020 Dec; 38(5):654-664.
    View in: PubMed
    Score: 0.013
  55. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia. 2021 03; 35(3):691-700.
    View in: PubMed
    Score: 0.013
  56. Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. Am J Hematol. 2019 12; 94(12):1388-1395.
    View in: PubMed
    Score: 0.012
  57. Persistence of peripheral blood and bone marrow blasts during remission induction in adult acute lymphoblastic leukemia confers a poor prognosis depending on treatment intensity. Clin Cancer Res. 1999 Sep; 5(9):2491-7.
    View in: PubMed
    Score: 0.012
  58. Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. J Clin Oncol. 1998 Oct; 16(10):3279-85.
    View in: PubMed
    Score: 0.011
  59. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674.
    View in: PubMed
    Score: 0.011
  60. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma. 2019 01; 60(1):37-48.
    View in: PubMed
    Score: 0.011
  61. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer. 2018 06 15; 124(12):2534-2540.
    View in: PubMed
    Score: 0.011
  62. Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations. Int J Hematol. 2018 Jun; 107(6):689-695.
    View in: PubMed
    Score: 0.011
  63. Natural history and staging of chronic myelogenous leukaemia. Baillieres Clin Haematol. 1997 Jun; 10(2):277-90.
    View in: PubMed
    Score: 0.010
  64. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. Oncotarget. 2017 Mar 28; 8(13):22104-22112.
    View in: PubMed
    Score: 0.010
  65. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol. 2017 Mar; 92(3):238-243.
    View in: PubMed
    Score: 0.010
  66. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2016 Dec 15; 122(24):3812-3820.
    View in: PubMed
    Score: 0.010
  67. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. Am J Hematol. 2016 Jun; 91(4):385-9.
    View in: PubMed
    Score: 0.009
  68. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016 Feb; 172(3):392-400.
    View in: PubMed
    Score: 0.009
  69. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood. 2015 Oct 01; 126(14):1699-706.
    View in: PubMed
    Score: 0.009
  70. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015 Aug 06; 126(6):790-7.
    View in: PubMed
    Score: 0.009
  71. Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. Clin Lymphoma Myeloma Leuk. 2015 Sep; 15(9):556-62.
    View in: PubMed
    Score: 0.009
  72. Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome. Leuk Res. 2015 Aug; 39(8):822-7.
    View in: PubMed
    Score: 0.009
  73. Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis. J Hematol Oncol. 2015 Apr 08; 8:32.
    View in: PubMed
    Score: 0.009
  74. Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. Leuk Lymphoma. 2015 Jul; 56(7):2092-7.
    View in: PubMed
    Score: 0.009
  75. Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes. Leukemia. 1994 Dec; 8(12):2174-8.
    View in: PubMed
    Score: 0.009
  76. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014 Oct; 14(5):401-10.
    View in: PubMed
    Score: 0.008
  77. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. Am J Hematol. 2014 Apr; 89(4):395-8.
    View in: PubMed
    Score: 0.008
  78. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leuk Lymphoma. 2014 Aug; 55(8):1925-9.
    View in: PubMed
    Score: 0.008
  79. Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):163-71.
    View in: PubMed
    Score: 0.008
  80. Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy. Clin Lymphoma Myeloma Leuk. 2014 Aug; 14(4):327-334.e8.
    View in: PubMed
    Score: 0.008
  81. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014 Jan 23; 123(4):494-500.
    View in: PubMed
    Score: 0.008
  82. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014 Jun; 28(6):1280-8.
    View in: PubMed
    Score: 0.008
  83. Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):93-7.
    View in: PubMed
    Score: 0.008
  84. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2014 Jan; 20(1):89-97.
    View in: PubMed
    Score: 0.008
  85. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leuk Lymphoma. 2014 Jun; 55(6):1337-44.
    View in: PubMed
    Score: 0.008
  86. Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome. Leuk Res. 2013 Nov; 37(11):1472-6.
    View in: PubMed
    Score: 0.008
  87. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood. 2013 Oct 17; 122(16):2807-11; quiz 2920.
    View in: PubMed
    Score: 0.008
  88. Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). Blood. 2013 Sep 12; 122(11):1974-82.
    View in: PubMed
    Score: 0.008
  89. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013 Aug 15; 122(7):1214-21.
    View in: PubMed
    Score: 0.008
  90. A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia. Br J Haematol. 2013 Oct; 163(1):130-2.
    View in: PubMed
    Score: 0.008
  91. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013 Aug 08; 122(6):872-84.
    View in: PubMed
    Score: 0.008
  92. Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):592-6.
    View in: PubMed
    Score: 0.008
  93. Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):435-40.
    View in: PubMed
    Score: 0.008
  94. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia. 2013 Oct; 27(10):2081-3.
    View in: PubMed
    Score: 0.008
  95. Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation. Leuk Lymphoma. 2014 Jan; 55(1):121-7.
    View in: PubMed
    Score: 0.008
  96. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013 Jun 06; 121(23):4655-62.
    View in: PubMed
    Score: 0.008
  97. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol. 2013 May; 88(5):365-9.
    View in: PubMed
    Score: 0.008
  98. Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis. Leuk Lymphoma. 2013 Nov; 54(11):2537-9.
    View in: PubMed
    Score: 0.008
  99. Is acute myeloid leukemia a liquid tumor? Int J Cancer. 2013 Aug 01; 133(3):534-43.
    View in: PubMed
    Score: 0.008
  100. Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):315-318.e2.
    View in: PubMed
    Score: 0.008
  101. Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):131-8.
    View in: PubMed
    Score: 0.008
  102. Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):153-8.
    View in: PubMed
    Score: 0.008
  103. Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Leukemia. 2013 Apr; 27(4):836-42.
    View in: PubMed
    Score: 0.007
  104. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia. 2013 Apr; 27(4):907-13.
    View in: PubMed
    Score: 0.007
  105. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol. 2013 Jan; 88(1):56-9.
    View in: PubMed
    Score: 0.007
  106. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood. 2012 Dec 06; 120(24):4840-5.
    View in: PubMed
    Score: 0.007
  107. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013 Jan; 27(1):107-12.
    View in: PubMed
    Score: 0.007
  108. Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. Haematologica. 2012 Aug; 97(8):1242-5.
    View in: PubMed
    Score: 0.007
  109. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012 Aug; 12(4):244-51.
    View in: PubMed
    Score: 0.007
  110. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer. 2012 May 15; 118(10):2665-73.
    View in: PubMed
    Score: 0.007
  111. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol. 2011 Nov 01; 29(31):4088-95.
    View in: PubMed
    Score: 0.007
  112. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood. 2011 Nov 17; 118(20):5697-700.
    View in: PubMed
    Score: 0.007
  113. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1874-7.
    View in: PubMed
    Score: 0.007
  114. Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. J Clin Oncol. 2011 Jun 20; 29(18):2507-13.
    View in: PubMed
    Score: 0.007
  115. Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. Cancer. 2011 Nov 15; 117(22):5085-93.
    View in: PubMed
    Score: 0.007
  116. Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia? Leuk Lymphoma. 2011 Jun; 52(6):1010-6.
    View in: PubMed
    Score: 0.007
  117. Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications. Clin Lymphoma Myeloma Leuk. 2011 Apr; 11(2):237-41.
    View in: PubMed
    Score: 0.007
  118. Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. Haematologica. 2011 Jun; 96(6):918-21.
    View in: PubMed
    Score: 0.007
  119. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer. 2011 May 15; 117(10):2145-55.
    View in: PubMed
    Score: 0.007
  120. Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Cancer. 2010 Sep 01; 116(17):4063-8.
    View in: PubMed
    Score: 0.006
  121. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer. 2010 Dec 15; 116(24):5568-74.
    View in: PubMed
    Score: 0.006
  122. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 2010 Aug 15; 116(16):3830-4.
    View in: PubMed
    Score: 0.006
  123. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010 Nov 25; 116(22):4422-9.
    View in: PubMed
    Score: 0.006
  124. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010 Aug 20; 28(24):3880-9.
    View in: PubMed
    Score: 0.006
  125. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer. 2010 May 01; 116(9):2174-9.
    View in: PubMed
    Score: 0.006
  126. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol. 2010 Jun 01; 28(16):2755-60.
    View in: PubMed
    Score: 0.006
  127. Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission. Leuk Lymphoma. 2010 Mar; 51(3):475-80.
    View in: PubMed
    Score: 0.006
  128. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2010 Feb 11; 115(6):1131-6.
    View in: PubMed
    Score: 0.006
  129. Allogeneic hematopoietic cell transplant for prolymphocytic leukemia. Biol Blood Marrow Transplant. 2010 Apr; 16(4):543-7.
    View in: PubMed
    Score: 0.006
  130. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res. 2010 Jun; 34(6):752-6.
    View in: PubMed
    Score: 0.006
  131. Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Leukemia. 2009 Dec; 23(12):2275-80.
    View in: PubMed
    Score: 0.006
  132. Azacitidine for the treatment of myelodysplastic syndrome. Expert Rev Anticancer Ther. 2009 Jul; 9(7):875-84.
    View in: PubMed
    Score: 0.006
  133. Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome. Clin Cancer Res. 2009 Jun 01; 15(11):3820-6.
    View in: PubMed
    Score: 0.006
  134. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol. 2009 Apr 01; 27(10):1637-43.
    View in: PubMed
    Score: 0.006
  135. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood. 2009 Apr 30; 113(18):4171-8.
    View in: PubMed
    Score: 0.006
  136. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer. 2008 Dec 01; 113(11):3186-91.
    View in: PubMed
    Score: 0.006
  137. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008 Sep 15; 113(6):1351-61.
    View in: PubMed
    Score: 0.006
  138. Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia. Leuk Res. 2009 Feb; 33(2):212-7.
    View in: PubMed
    Score: 0.006
  139. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009 Jun 18; 113(25):6330-7.
    View in: PubMed
    Score: 0.006
  140. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008 Aug 15; 112(4):975-80.
    View in: PubMed
    Score: 0.005
  141. The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients. Clin Cancer Res. 2008 Feb 01; 14(3):721-30.
    View in: PubMed
    Score: 0.005
  142. An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation. Leuk Res. 2008 Jun; 32(6):936-43.
    View in: PubMed
    Score: 0.005
  143. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008 Mar; 22(3):538-43.
    View in: PubMed
    Score: 0.005
  144. Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment. Cancer J. 2007 Nov-Dec; 13(6):357-65.
    View in: PubMed
    Score: 0.005
  145. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer. 2007 Oct 01; 110(7):1509-19.
    View in: PubMed
    Score: 0.005
  146. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy. Leuk Res. 2008 Apr; 32(4):643-9.
    View in: PubMed
    Score: 0.005
  147. Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System. Leuk Lymphoma. 2007 Jun; 48(6):1150-60.
    View in: PubMed
    Score: 0.005
  148. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer. 2007 Mar 15; 109(6):1133-7.
    View in: PubMed
    Score: 0.005
  149. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007 Jun 01; 109(11):4679-85.
    View in: PubMed
    Score: 0.005
  150. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol. 2007 Feb; 136(4):624-7.
    View in: PubMed
    Score: 0.005
  151. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer. 2007 Jan 15; 109(2):265-73.
    View in: PubMed
    Score: 0.005
  152. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006 Sep 15; 108(6):1809-20.
    View in: PubMed
    Score: 0.005
  153. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006 Mar 01; 106(5):1090-8.
    View in: PubMed
    Score: 0.005
  154. T-cell prolymphocytic leukemia: a single-institution experience. Clin Lymphoma Myeloma. 2005 Nov; 6(3):234-9.
    View in: PubMed
    Score: 0.005
  155. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer. 2005 Aug 01; 104(3):547-54.
    View in: PubMed
    Score: 0.004
  156. Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. Mayo Clin Proc. 2005 Mar; 80(3):390-402.
    View in: PubMed
    Score: 0.004
  157. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004 Dec 15; 101(12):2788-801.
    View in: PubMed
    Score: 0.004
  158. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer. 2004 Sep 01; 101(5):999-1008.
    View in: PubMed
    Score: 0.004
  159. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood. 2004 Sep 15; 104(6):1624-30.
    View in: PubMed
    Score: 0.004
  160. C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome. Leuk Res. 2004 Apr; 28(4):373-8.
    View in: PubMed
    Score: 0.004
  161. Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy. Cancer. 2004 Feb 01; 100(3):568-73.
    View in: PubMed
    Score: 0.004
  162. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):68-75.
    View in: PubMed
    Score: 0.004
  163. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer. 2003 Dec 15; 98(12):2636-42.
    View in: PubMed
    Score: 0.004
  164. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. Cancer. 2003 Oct 01; 98(7):1430-7.
    View in: PubMed
    Score: 0.004
  165. Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia. Leuk Res. 2003 Jul; 27(7):661-9.
    View in: PubMed
    Score: 0.004
  166. Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications. Cancer. 2003 Jul 01; 98(1):81-5.
    View in: PubMed
    Score: 0.004
  167. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003 Oct 01; 102(7):2379-86.
    View in: PubMed
    Score: 0.004
  168. Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia. Cancer. 2003 May 01; 97(9):2212-7.
    View in: PubMed
    Score: 0.004
  169. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol. 2003 May 01; 21(9):1722-7.
    View in: PubMed
    Score: 0.004
  170. A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression. Br J Haematol. 2003 May; 121(4):578-85.
    View in: PubMed
    Score: 0.004
  171. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2003 Apr 01; 97(7):1711-20.
    View in: PubMed
    Score: 0.004
  172. Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse. Clin Adv Hematol Oncol. 2003 Apr; 1(4):220-5.
    View in: PubMed
    Score: 0.004
  173. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer. 2003 Feb 15; 97(4):1033-41.
    View in: PubMed
    Score: 0.004
  174. Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival. Br J Haematol. 2002 Oct; 119(1):38-45.
    View in: PubMed
    Score: 0.004
  175. Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. Leukemia. 2002 Sep; 16(9):1615-21.
    View in: PubMed
    Score: 0.004
  176. Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol. 2002 Jul; 118(1):151-6.
    View in: PubMed
    Score: 0.004
  177. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 2002 Jul; 8(7):2167-76.
    View in: PubMed
    Score: 0.004
  178. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002 May 15; 99(10):3547-53.
    View in: PubMed
    Score: 0.004
  179. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer. 2002 Apr 01; 94(7):2024-32.
    View in: PubMed
    Score: 0.004
  180. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood. 2002 Mar 15; 99(6):2265-7.
    View in: PubMed
    Score: 0.004
  181. Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia. Cancer. 2002 Mar 01; 94(5):1517-21.
    View in: PubMed
    Score: 0.004
  182. Central nervous system relapse in adults with acute lymphoblastic leukemia. Cancer. 2002 Feb 01; 94(3):773-9.
    View in: PubMed
    Score: 0.004
  183. Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. Cancer. 2001 Nov 15; 92(10):2501-7.
    View in: PubMed
    Score: 0.003
  184. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer. 2001 Oct 15; 92(8):1999-2015.
    View in: PubMed
    Score: 0.003
  185. Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance. Cancer. 2001 Jun 01; 91(11):1964-72.
    View in: PubMed
    Score: 0.003
  186. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Cancer. 2000 Nov 01; 89(9):1976-82.
    View in: PubMed
    Score: 0.003
  187. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol. 2000 Oct 15; 18(20):3513-21.
    View in: PubMed
    Score: 0.003
  188. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin Cancer Res. 2000 Apr; 6(4):1401-9.
    View in: PubMed
    Score: 0.003
  189. Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: correlation with disease progression and response to therapy. Cancer. 2000 Feb 01; 88(3):570-6.
    View in: PubMed
    Score: 0.003
  190. Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia. Clin Cancer Res. 2000 Jan; 6(1):147-52.
    View in: PubMed
    Score: 0.003
  191. Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance. Br J Haematol. 1999 Dec; 107(3):581-6.
    View in: PubMed
    Score: 0.003
  192. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer. 1999 Oct 01; 86(7):1216-30.
    View in: PubMed
    Score: 0.003
  193. Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance. Cancer. 1999 Sep 01; 86(5):805-13.
    View in: PubMed
    Score: 0.003
  194. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol. 1999 Sep; 17(9):2819-30.
    View in: PubMed
    Score: 0.003
  195. The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia. Clin Cancer Res. 1999 Jul; 5(7):1855-61.
    View in: PubMed
    Score: 0.003
  196. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood. 1999 Apr 15; 93(8):2478-84.
    View in: PubMed
    Score: 0.003
  197. Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance. Blood. 1999 Mar 15; 93(6):2075-80.
    View in: PubMed
    Score: 0.003
  198. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol. 1999 Jan; 17(1):284-92.
    View in: PubMed
    Score: 0.003
  199. Determinants of prognosis in late chronic-phase chronic myelogenous leukemia. J Clin Oncol. 1998 Dec; 16(12):3782-7.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.